Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Musa Yilmaz

Showing results (81-90 of 160) with videos related to

Pageof 16
Sort By:
Leukemia & Lymphoma|January 12, 2019
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosisPrithviraj Bose, Mahesh Swaminathan, Naveen Pemmaraju, et al.
Cancer|April 7, 2025
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trialHannah Goulart, Hagop Kantarjian, Gautam Borthakur, et al.
Cancer|July 17, 2019
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemiaKoji Sasaki, Hagop M Kantarjian, Tapan Kadia, et al.
American Journal of Hematology|January 23, 2023
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitorsElias J Jabbour, Koji Sasaki, Fadi G Haddad, et al.
Cancer|March 13, 2019
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndromeKiran Naqvi, Koji Sasaki, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology|March 28, 2024
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trialAlexandre Bazinet, Hagop Kantarjian, Alex Bataller, et al.
Leukemia & Lymphoma|March 31, 2025
Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletionsEitan Kugler, Enes Dasdemir, Alex Bataller, et al.
American Journal of Hematology|May 15, 2023
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1Nicholas J Short, Elias Jabbour, Walid Macaron, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
Blood Cancer Journal|January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapySangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
Pageof 16

Showing results (81-90 of 160) with videos related to

Sort By:
Pageof 16
Leukemia & Lymphoma|January 12, 2019
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosisPrithviraj Bose, Mahesh Swaminathan, Naveen Pemmaraju, et al.
Cancer|April 7, 2025
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trialHannah Goulart, Hagop Kantarjian, Gautam Borthakur, et al.
Cancer|July 17, 2019
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemiaKoji Sasaki, Hagop M Kantarjian, Tapan Kadia, et al.
American Journal of Hematology|January 23, 2023
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitorsElias J Jabbour, Koji Sasaki, Fadi G Haddad, et al.
Cancer|March 13, 2019
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndromeKiran Naqvi, Koji Sasaki, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology|March 28, 2024
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trialAlexandre Bazinet, Hagop Kantarjian, Alex Bataller, et al.
Leukemia & Lymphoma|March 31, 2025
Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletionsEitan Kugler, Enes Dasdemir, Alex Bataller, et al.
American Journal of Hematology|May 15, 2023
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1Nicholas J Short, Elias Jabbour, Walid Macaron, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
Blood Cancer Journal|January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapySangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
Pageof 16